ImmunoGen (BMV:IMGN *) - Aandelenkoers, Nieuws & Analyse

IMGN * Overzicht aandelen

ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. Meer informatie

IMGN * fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	6/6
Prestaties in het verleden	0/6
Financiële gezondheid	4/6
Dividenden	0/6

Beloningen

De winst zal naar verwachting met 45.17% per jaar groeien

Risicoanalyse

Aandelen zijn zeer illiquide

Aandeelhouders zijn het afgelopen jaar verwaterd

ImmunoGen, Inc. Concurrenten

Innovent Biologics

SEHK:1801

HK$60.8b

Swedish Orphan Biovitrum

OM:SOBI

SEK 102.5b

Imeik Technology DevelopmentLtd

SZSE:300896

CN¥60.9b

Shanghai RAAS Blood Products

SZSE:002252

CN¥49.1b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor ImmunoGen
Historische aandelenkoersen
Huidige aandelenkoers	US$268.50
52 Week Hoogtepunt	US$330.00
52 Week Laag	US$101.20
Bèta	1.17
11 maand verandering	0%
3 maanden verandering	n/a
1 Jaar Verandering	96.13%
33 jaar verandering	87.76%
5 jaar verandering	n/a
Verandering sinds IPO	595.42%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	IMGN *	MX Biotechs	MX Markt
7D	0%	0%	0%
1Y	96.1%	0%	0%

Rendement versus industrie: IMGN * overtrof de MX Biotechs industrie, die het afgelopen jaar een rendement 9.4 % opleverde.

Rendement versus markt: IMGN * overtrof de MX markt, die het afgelopen jaar een rendement opleverde van -4 %.

Prijsvolatiliteit

Is IMGN *'s price volatile compared to industry and market?
IMGN * volatility
IMGN * Average Weekly Movement	n/a
Biotechs Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in MX Market	0%
10% least volatile stocks in MX Market	0%

Stabiele aandelenkoers: IMGN * heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van IMGN * in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1980	277	Mark Enyedy	www.immunogen.com

ImmunoGen, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van ImmunoGen zich tot de beurswaarde?
IMGN * fundamentele statistieken
Marktkapitalisatie	Mex$142.79b
Inkomsten(TTM)	-Mex$1.26b
Inkomsten(TTM)	Mex$4.91b

29.1x

P/S-verhouding

-113.7x

Koers/Winstverhouding

Is IMGN * overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
IMGN * resultatenrekening (TTM)
Inkomsten	US$287.61m
Kosten van inkomsten	US$211.62m
Brutowinst	US$76.00m
Overige uitgaven	US$149.52m
Inkomsten	-US$73.52m

Laatst gerapporteerde inkomsten

Sep 30, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.27
Brutomarge	26.42%
Nettowinstmarge	-25.56%
Schuld/Eigen Vermogen Verhouding	12.8%

Hoe presteerde IMGN * op de lange termijn?

Bekijk historische prestaties en vergelijking

IMGN * Overzicht aandelen

Beloningen

Risicoanalyse

ImmunoGen, Inc. Concurrenten

SEHK:1801

HK$60.8b

OM:SOBI

SEK 102.5b

SZSE:300896

CN¥60.9b

SZSE:002252

CN¥49.1b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

ImmunoGen Files Form 15

ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

Forecast to breakeven in 2023

FDA Grants Priority Review of ImmunoGen, Inc.'s Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer

Recent updates

ImmunoGen Files Form 15

ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

ImmunoGen, Inc. Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH

Forecast to breakeven in 2023

FDA Grants Priority Review of ImmunoGen, Inc.'s Supplemental Biologics License Application for ELAHERE in Platinum-Resistant Ovarian Cancer

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.4 billion.

Forecast breakeven date moved forward to 2023

ImmunoGen Announces European Medicines Agency Acceptance of Marketing Authorization Application for Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer

Forecast breakeven date moved forward to 2024

ImmunoGen, Inc. Announces Executive Changes

Immunogen, Inc. Reaffirmes Revenue Guidance for 2023

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen Inc. Presents Updated Findings from CADENZA Trial of Pivekimab Sunirine in Blastic Plasmacytoid Dendritic Cell Neoplasm at EHA 2023 Congress

ImmunoGen Inc. Announces Detailed Results from the Phase 3 Confirmatory MIRASOL Trial (GOG 3045/ENGOT OV-55) Evaluating the Safety and ELAHERE

ImmunoGen, Inc. Announces ELAHERE Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRa-Positive Platinum-Resistant Ovarian Cancer

Forecast to breakeven in 2025

No longer forecast to breakeven

Full year 2022 earnings released: US$0.88 loss per share (vs US$0.68 loss in FY 2021)

Forecast to breakeven in 2025

Immunogen, Inc. Appoints Michael Vasconcelles as Executive Vice President, Research, Development, and Medical Affairs

ImmunoGen, Inc. Announces Executive Changes

ImmunoGen, Inc. Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH

ImmunoGen, Inc. Appoints Daniel Char as Senior Vice President and Chief Legal Officer

NeoGenomics and ImmunoGen Launches New Program Giving Ovarian Cancer Patients Access to Novel Fr Biomarker Testing to Support the Launch of Elahere(Tm)

ImmunoGen, Inc. Announces US Food and Drug Administration Grants Accelerated Approval of ELAHERE™ for the Treatment of Platinum-Resistant Ovarian Cancer

Third quarter 2022 earnings released: US$0.31 loss per share (vs US$0.18 loss in 3Q 2021)

ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022

ImmunoGen, Inc. Announces Departure of Kristen Harrington-Smith as Senior Vice President Chief Commercial Officer

ImmunoGen Presents Additional Analyses Evaluating Mirvetuximab Soravtansine in Ovarian Cancer at ESMO

ImmunoGen, Inc. Provides Update on Pivotal CADENZA Study of Pivekimab Sunirine in Frontline Blastic Plasmacytoid Dendritic Cell Neoplasm

ImmunoGen, Inc. Provides Earnings Guidance for the Year 2022

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.15 loss in 2Q 2021)

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

ImmunoGen, Inc. Samenvatting

29.1x

-113.7x

Inkomsten en omzet